AMI:To evaluate the clinical efficacy of the segmented bifocal intraocular lens(MIOL)SBL-3.

METHODS:Totally 26 cases(26 eyes)of age-related cataract who received phacoemulsification and implantation of MIOL SBL-3 were enrolled from February 2016 to June 2017 in our hospital as the SBL-3 group. And 28 cases(28 eyes)of age-related cataract who received phacoemulsification and implantation of single focus intraocular lens intraocular lens TecnisZA9003 were enrolled as control group. At postoperative 3mo, the uncorrected visual acuity, corrected visual acuity, contrast sensitivity and patient satisfaction were compared between two groups.

RESULTS: At preoperative, there was no statistical difference in uncorrected distance, intermediate and near visual acuity between two groups(P>0.05). At postoperatively 3mo, the uncorrected distance, intermediate and near visual acuity in patients of both groups were significantly improved(P<0.05). At postoperative 3mo, the uncorrected intermediate and near visual acuity, distance-corrected intermediate and near visual acuity, contrast sensitivity at different spatial frequencies(3, 6, 12, 18c/d)and patient satisfaction in SBL-3 group were significantly better than those of control group(P<0.05).

CONCLUSION: The MIOL SBL-3 not only could provide preferable distance visual acuity, but also could provide better intermediate visual acuity, near visual acuity and contrast sensitivity, and greatly increase the visual quality and satisfaction at postoperative in cataract patients.